News

News

Press Releases

May 06, 2021
Tricida Announces First Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO , May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed
Apr 08, 2021
Tricida to Present at the Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET . Tricida will provide a company overview, business
Feb 25, 2021
Tricida Announces Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic
Feb 25, 2021
Tricida Provides Update on FDA Interactions
Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and